KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Cash & Current Investments: 2011-2025

Historic Cash & Current Investments for Sarepta Therapeutics (SRPT) over the last 15 years, with Sep 2025 value amounting to $851.0 million.

  • Sarepta Therapeutics' Cash & Current Investments fell 28.99% to $851.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.1 billion, marking a year-over-year decrease of 39.08%. This contributed to the annual value of $1.4 billion for FY2024, which is 48.29% down from last year.
  • Per Sarepta Therapeutics' latest filing, its Cash & Current Investments stood at $851.0 million for Q3 2025, which was down 11.62% from $963.0 million recorded in Q2 2025.
  • Over the past 5 years, Sarepta Therapeutics' Cash & Current Investments peaked at $2.6 billion during Q4 2023, and registered a low of $851.0 million during Q3 2025.
  • In the last 3 years, Sarepta Therapeutics' Cash & Current Investments had a median value of $1.4 billion in 2024 and averaged $1.5 billion.
  • Its Cash & Current Investments has fluctuated over the past 5 years, first spiked by 31.69% in 2023, then plummeted by 48.29% in 2024.
  • Quarterly analysis of 5 years shows Sarepta Therapeutics' Cash & Current Investments stood at $2.1 billion in 2021, then dropped by 5.98% to $2.0 billion in 2022, then skyrocketed by 31.69% to $2.6 billion in 2023, then slumped by 48.29% to $1.4 billion in 2024, then fell by 28.99% to $851.0 million in 2025.
  • Its Cash & Current Investments was $851.0 million in Q3 2025, compared to $963.0 million in Q2 2025 and $894.2 million in Q1 2025.